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Abstract
Vancomycin resistance in Staphylococcus aureus has emerged over the last ten years due to varying mechanisms and giving variable
levels of resistance to vancomycin. The most resistant strains (fortunately rare) bear the vanA gene cluster and these are generally
recognisable as MICs of vancomycin are usually found to be in the range 32-64mg/L. It should be noted that some automated
systems have failed to detect these isolates. The much more commonly encountered GISA and hGISA vancomycin resistant strains
of MRSA and methicillin sensitive Staph. aureus (MSSA) exhibit lower levels of resistance and difﬁculty is encountered in reliably
deﬁning and identifying these strains in clinical laboratories. No single completely reliable, convenient test either phonotypical
genetic currently exists which can be readily applied in the clinical laboratory for the detection of hGISA/GISA. The population ana-
lysis proﬁle (PAP) method is currently regarded as the reference method but is slow and tedious to perform on a large number
of isolates. This enables the differentiation of hGISA and GISA from fully vancomycin sensitive strains. In the clinical laboratory the
use of Meuller-Hinton agar with 5mg/L teicoplanin and a 10lL innoculum of MacFarland 0.5 incubated for 48h represents the most
reliable and economical screening test. Further conﬁrmation would be required using either macrodilution Etest methodology using
an MIC ‡ 8mg/L of vancomycin and/or teicoplanin as the cut off for hGISA or the newer GRD (glycopeptide resistance detection)
strip.
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Introduction
There has been a substantial increase in nosocomial
infections caused by methicillin-resistant Staphylococcus
aureus (MRSA) in the UK, and this has been replicated in
many parts of the world [1]. The mainstay of treatment
for infections caused by MRSA has been and currently
remains vancomycin. In consequence, usage is heavy, par-
ticularly with the availability of HPLC-puriﬁed formulations
with reduced side effects [2]. Entirely predictably, this
increased selective pressure has led to the emergence of
vancomycin resistance in S. aureus and in MRSA strains in
particular.
Vancomycin-Resistant S. aureus (VRSA)
The principal mode of action of vancomycin depends on the
molecule binding to the D-alanyl-D-alanine peptide tail of
the cell wall peptide glycan precursor. The cleavage of the
D-Ala-D-Ala residue (DDR) by transpeptidases and, possibly,
transglycosylation are subject to steric interference by the
bulky vancomycin molecule, leading to failure to incorporate
new peptidoglycan monomers into the cell wall and to sub-
sequent cell death. The most frequently encountered type of
transferable, high-level resistance to vancomycin is found in
enterococci, and is of the VanA type [3]. It is carried on a
transposon, Tn1546, and related elements that encode a
dehydrogenase (VanH), which reduces pyruvate to D-Lac,
and the VanA ligase, which catalyses the formation of an
ester bond between D-Ala and D-Lac. The resulting D-Ala-D-
Lac depsipeptide replaces the D-Ala-D-Ala dipeptide in pepti-
doglycan synthesis, a substitution that considerably decreases
the afﬁnity of the molecule for glycopeptides.
The emergence of high-level transferable vancomycin
resistance (vanA type), which was later shown to be medi-
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ated by a conjugative transposon in Enterococcus faecium in
Dulwich, London in 1987 [4], was initially thought to be
the most likely route for the widespread emergence of
vancomycin resistance in S. aureus. Noble et al. [5] demon-
strated many years ago that the vanA gene from Enterococ-
cus faecalis, which is present on the conjugative transposon
Tn1546, was capable of transfer into some strains of
S. aureus and then being expressed, thus resulting in very
high MICs of vancomycin (‡256 mg/L). This is the most
feared mechanism of resistance to vancomycin in S. aureus
and, bearing in mind that MRSA and vancomycin-resistant
enterococci frequently coexist in patients treated with
vancomycin in a hospital setting, it seemed inevitable that
vanA-bearing vancomycin-resistant S. aureus would emerge
(these strains are referred to as VRSA). It was not until
2002 that the ﬁrst isolate of MRSA bearing the vanA gene
cluster was identiﬁed in the USA [6]. Unexpectedly, to
date, only single-digit numbers of MRSA strains carrying
and expressing the vanA gene have been identiﬁed [7].
However, all are unique strains that most probably repre-
sent one-off horizontal gene transfer events, suggesting
that the threat is a continuing one [8]. Worryingly, VRSA
has also been reported recently from India, where two
strains were found in a recent survey, although genetic
analysis of these VRSA strains has not been reported [9].
The delay in the emergence of VRSA may well be
explained by the fact that many lineages of S. aureus iden-
tiﬁed by multilocus sequence typing carry a speciﬁc restric-
tion system (sau type 1 restriction modiﬁcation system)
that destroys incoming DNA, thus making it difﬁcult for
foreign DNA from bacteria such as enterococci to enter
the cell and replicate [10]. It might be expected that the
detection of VRSA is simple, and although the MICs of
vancomycin are high for some strains (1024 and 256 mg/L
for the Michigan and New York isolates, respectively), that
for the strain from Pennsylvania was only 32 mg/L [7].
Further investigation of the Pennsylvania strain showed
that although the vanA gene cluster is carried on a 120-kb
plasmid, as in the New York strain, it is not stably
expressed, serial passage leading to restoration of sensitiv-
ity to vancomycin [11]. Currently, it is suggested that
VRSA should be detected by the same methods as used
for glycopeptide-intermediate S. aureus (GISA)/heteroge-
neous GISA (hGISA) [12], the higher MICs of vancomycin
perhaps giving a clue to the different mechanisms of resis-
tance. It is important to note that neither the Pennsylvania
nor the New York strain was detected by automated
methods, despite having MICs of vancomycin of 32–64 mg/
L [13].
GISA and hGISA
Much more common are GISA and hGISA vancomycin-resis-
tant strains of MRSA and methicillin-sensitive S. aureus that
exhibit a range of phenotypes expressing lower levels of
resistance to vancomycin (vancomycin-intermediate S. aureus
(VISA)). The resistance is not restricted to vancomycin, and
outside the USA, where glycopeptides other than vanco-
mycin are available (e.g. teicoplanin), the term GISA is more
widely used, and will be adopted in this review. The study of
this phenomenon is complicated by the observation made
early in the study of GISA that the population of these
strains is often heterogeneous [14]. The ﬁrst isolate from
Japan (Mu3) had a vancomycin MIC of 4 mg/L, with much
smaller numbers of cells (as few as 10)6 CFU) which, when
subcultured, had MICs of 5–9 mg/L. These strains were
termed heterogeneous VISA (hVISA), and were thought to
give rise to VISA strains with higher, more stable levels of
resistance; they are usually MRSA [15].
The deﬁnitions of VRSA, GISA and hGISA are bedevilled
not only by variations arising from testing methodologies,
but also by changes in the MIC deﬁnitions. The results of an
important study of an international collection of 20 GISA
and 157 hGISA strains demonstrated that reducing the MIC
breakpoint from 4 to 2 mg/L led to correct classiﬁcation of
100% of VISA strains as intermediate, whereas, with the
higher breakpoint, only 45% were identiﬁed as intermediate
[16]. In the case of hVISA strains, with the lower breakpoint,
17.8% were classiﬁed as intermediate, as opposed to 0% with
the higher breakpoint, highlighting the need for a supplemen-
tary testing methodology to identify hGISA strains.
In 2006, the CLSI revised the clinical vancomycin break-
points to £2 mg/L for sensitive strains, 4–8 mg/L for GISA,
and ‡16 mg/L for VRSA [17]. This redeﬁnition means that
many of the strains deﬁned by MIC in the Liu & Chambers
review as hGISA are, according to CLSI criteria, GISA
strains. This emphasizes the difﬁculty in comparing studies of
GISA, particularly across different time periods. The
vancomycin and teicoplanin breakpoints currently adopted
by EUCAST are 2/2 mg/L sensitive/intermediate resistant
(http://www.srga.org/eucastwt/mictab/MICglycopeptides_v2.
html).
Resistance Mechanisms of GISA
GISA and hGISA strains, unlike VRSA strains, that have
acquired the vanA gene cluster, do not have a fully under-
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stood mechanism of resistance. It has been clearly estab-
lished that a thickened cell wall is the constant feature of
GISA. This was ﬁrst demonstrated for the Japanese strain
Mu50 [18], and subsequently for a collection of 16 strains
(all had MICs of vancomycin of 8 mg/L) from seven coun-
tries [19]. Passage of these strains in drug -free medium
gave rise to isolates with reduced resistance (MIC of
<4 mg/L). All of the strains, with one exception, still pos-
sessed subpopulations that were resistant to vancomycin
according to population analysis (i.e. hGISA), and these
could give rise to GISA by reselection with vancomycin
[19]. The thickened cell wall is not the only feature of
Mu50, as accelerated peptidoglycan synthesis and an
increase in the glutamic non-amidated muropeptide compo-
nent have also been identiﬁed [18].
The hypothesis for the resistance mechanisms of GISA is
that the thickened cell wall reduces the coefﬁcient of diffu-
sion of vancomycin through the cell wall. This reduces the
amount of vancomycin that is available to interact with the
DDR of the lipid II precursor. It is known that there are
approximately 106 free DDRs in the peptidoglycan of a single
S. aureus cell wall that can bind vancomycin. This prevents
vancomycin reaching the monomer DDRs, which are the key
targets for interference with peptidoglycan synthesis. Recent
work measuring the cell wall thickness of GISA and using
mathematical modelling suggests that ‘clogging’ is an impor-
tant mechanism in GISA [20]. Further support for this con-
cept comes from the study of an isogenic series of isolates
of VISA from a single bacteraemic patient given vancomycin
[21]. These VISA isolates had an abnormal cell wall composi-
tion, with poor separation of daughter cells, when grown in
antibiotic-free medium. Vancomycin trapping was postulated
as a likely mechanism of resistance, as free DDRs were iden-
tiﬁed in the muropeptides. Cell wall biosynthesis pathways in
Mu50 have also been shown to be disordered, with several
mutations resulting in a loss of function of key enzyme path-
ways [22].
Mechanism of hVISA to VISA Conversion
With the revised CLSI breakpoints, hVISA will not be readily
detected even if the MIC of isolates is determined [23]. It
has therefore been necessary to devise methods for identify-
ing the small number of slightly more resistant hGISA cells
among large numbers of fully sensitive cells. Currently, this is
achieved using phenotypic methods, the most reliable being
population analysis proﬁling (PAP) [24]. A full understanding
of the genetic basis of heteroresistance and the processes
leading to conversion to GISA would potentially allow the
development of more sensitive/rapid genetic methods for
detection of hGISA/GISA. Despite extensive investigation of
isogenic strains, such as N315 (glycopeptide-sensitive
S. aureus (GSSA)), Mu3 (hGISA), and Mu50 (GISA), and sur-
veys of clinical isolates of hGISA/GISA, a complete under-
standing of the transition process eludes us [7,25]. What is
clear is that a range of regulator gene mutations can lead to
expression changes in enzyme pathways associated with cell
wall peptidoglycan synthesis, leading to cell wall thickening
and vancomycin resistance. Two regulatory genes have been
identiﬁed as possibly having a central role in this process:
VraS and graR [25,26]. Differential hybridization studies dem-
onstrated that the two-component regulatory system vraSR
is constitutively activated in Mu50 (GISA) and Mu3 (hGISA),
but strongly repressed in GSSA [27]. When S. aureus is
exposed to cell wall-active antibiotics such as vancomycin
and teicoplainin, provided that vraS, a histidine kinase sensor,
is intact, major changes are seen in the expression of multi-
ple genes associated with cell wall synthesis [28]. Inactivation
of vraS blocks the transcriptional response, resulting in signif-
icant reductions in susceptibility to glycopeptides and b-lacta-
mas [27]. Overexpression in the vancomycin-sensitive
S. aureus (VSSA) strain N315 of vraS leads to levels of vanco-
mycin resistance seen in hGISA but not in GISA [27]. Some
candidate enzyme pathway genes that are upregulated are
sgtB, murZ and other genes associated with peptidoglycan
synthesis pathways, such as that encoding penicillin-binding
protein 2 [27]. A working hypothesis to explain GISA strains
has evolved, in which mutations in vraSR, as part of the ‘cell
wall stimulon’, which positively modulates cell wall
biosynthetic pathways, is upregulated on exposure to cell
wall-active antibiotics [29], resulting in consistent upregula-
tion in GISA strains [30]. A comparative genomics study of
the genomes of Mu3, Mu5 and N315 identiﬁed a number of
putative genes involved in glycopeptide resistance, and one
(graR), when cloned, mutated, and re-introduced into the
hGISA strain Mu3, converted its phenotype to GISA; how-
ever, it failed to cause glycopeptide resistance in the GSSA
strain N315. This shows that the hGISA genetic environment
is necessary for the emergence of GISA; the authors specu-
lated that the activation of vraSR in Mu3, resulting in elevated
levels of cell wall synthesis enzymes, was the key to the
development of GISA [25]. The importance of the graRS
two-component regulatory system in the generation of
hGISA/GISA has been demonstrated with the advent of high-
throughput whole genome sequencing technologies. An iso-
genic pair (VSSA and GISA) of MRSA isolates from a patient
have undergone a nearly complete genome sequence com-
parison made recently [31]. The ﬁrst blood culture isolate
had a vancomycin MIC of 1 mg/L, and following 42 days of
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treatment, an isogenic blood culture isolate with an MIC of
4 mg/L, conﬁrmed as GISA by PAP, was obtained. Only six
nucleotide substitutions were identiﬁed between the two
genomic sequences; one of the mutations occurred in graS
(threonine to isoleucine at position 136). This resulted in a
change from polar to non-polar amino acids and, in contrast
to the ﬁndings of Neoh et al. [25], means that a single muta-
tion can generate an hGISA from a VSSA strain. Allelic
replacement of the mutated graS allele in the VSSA parent
strain generated a level of vancomycin resistance between
those of the VSSA and GISA strains, conﬁrming a role (but
not an exclusive role) for graRS in GISA. A recent compara-
tive transcription study suggests that graRS might control at
least 248 genes [32]. It has been shown to control vraF and
vraG, both of which are upregulated in GISA, a graR knock-
out mutant of Mu50 (GISA) showing increased susceptibility
to vancomycin [33].
As with many aspects of the GISA story, the apparently
straightforward results seen in Mu3/Mu50 are not repli-
cated in a wider range of isolates. In a study of teicopla-
nin-resistant GISA in Japan, possibly selected by heavy
usage of that drug, the mutated inactive form of vraS
(Ile5 ﬁ Asn) was seen in 99% of 78 intermediate teicopla-
nin-resistant strains; however, no increase in vancomycin
resistance was seen in those strains [34]. Further indirect
evidence of the importance of vraSR was the ﬁnding that
these genes were upregulated in daptomycin-resistant
mutants of MRSA generated in vitro that exhibited an
hGISA phenotype [35]. Point mutations resulting in inacti-
vation of agr, an important quorum-sensing global regula-
tory system, have been described in GISA strains but not
consistently [36,37]. Another process that may lead to a
thickened cell wall is a reduction in autolytic activity. Tran-
scriptomic and functional analysis of an isogenic pair of
teicoplanin-sensitive/resistant strains of S. aureus revealed
differences in autolytic properties between the strains that,
surprisingly, were not linked to changes in the transcrip-
tion of key autolytic effectors, but rather to post-transcrip-
tional processing or export [38]. The complexity of this
story is further compounded by recent work examining
the pattern of gene expression in ﬁve paired clinical
isolates of VSSA and hGISA/GISA. DNA sequencing of loci
that are important in global regulation, such as vraSR,
saeSR rot, merR, and mgrA, in isogenic strains failed to
deﬁne single mutations that were directly responsible for
the hGISA/GISA phenotype [39]. All of these data strongly
suggest that the emergence of the hGISA/GISA phenotype
requires mutations at a variety of loci, probably in different
combinations, leading to differences in transcriptional
pathways [31].
Phenotypic Methods for Identifying hGISA/
GISA
The clinical need to identify HGISA/GISA has been the sub-
ject of considerable controversy, not least because of the
application of inappropriate/insensitive methods for their
detection [40]. There is evidence that patients infected with
hGISA/GISA are most often those in which a glycopeptide
antibiotic has been administered for an extended period with
‘high-inoculum’ infections or in situations in which there is
heavy usage of glycopeptides [7,15]. One such study is that
reported by Maor et al. [41], conducted in 2003–2004 in Tel
Aviv, Israel, in which MRSA isolates from 264 patients with
bacteraemia were tested using the macrodilution Etest
method (MET). hGISA was found in 6% of the patients, MICs
of vancomycin were 1–4 mg/L, and 12 of 16 isolates would
have been misreported as susceptible to vancomycin if spe-
cial testing had not been used. Most signiﬁcantly, the mortal-
ity rate for all hGISA-infected patients was 75%, with a
directly attributed death rate of 50%. The authors did not
give a mortality rate for patients with MRSA bacteraemia to
compare with their ﬁndings; they did, however, cite a rate of
33% from a published meta-analysis [42]. In a French inten-
sive-care unit outbreak (1999–2000), extensive cross-infec-
tion from an index patient resulted in 21 patients being
infected/colonized by an hGISA strain; ﬁve patients died
either directly or partly due to the infection, which was not
detected by the then current CLSI methodology [43]. As will
be appreciated from the review in the ﬁrst part of this arti-
cle, hGISA and GISA share most genetic and phenotypic
characteristics (particularly an increase in cell wall thicken-
ing); in consequence, many experts now regard them practi-
cally as part of a continuum, rather than as distinct, stable
FIG. 1. Population analysis proﬁles for hetero-VISA strains Mu3 ())
and SMH2 (n), as well as Mu50 (a VISA strain) (s) and two repre-
sentative vancomycin-susceptible MRSA strains (s and h). Repro-
duced by permission [61].
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entities. GISA isolates do, however, produce a greater pro-
portion of cells with a higher glycopeptide MIC than hGISA
isolates. A number of phenotypic methods have been applied
to the detection of hGISA/GISA strains, with varying degrees
of sensitivity and speciﬁcity. The method used as the refer-
ence method is the PAP method [24]. This method was
developed in response to the ﬁnding that the ﬁrst described
method for the identiﬁcation of hGISA, by Hiramatsu et al.
(106 CFU/mL with inoculation onto brain–heart infusion agar
containing 4 mg/L vancomycin), did not reliably detect hGISA
[24]. The principle of this method relies on enumerating the
number of bacterial cells not inhibited by a series of concen-
trations of vancomycin around the breakpoint for sensitivity.
When the data are plotted graphically and compared with
those of a known hGISA strain, a numerical cut-off is applied
to the two areas under the curves (AUCs) to deﬁne a strain
as hGISA. Broth cultures of the strains to be treated are
incubated for 24 h in trypticase soy broth, diluted to 10)3
and 10)6, and plated using a spiral plater, which delivers an
increasingly diluted inoculum in a continuous spiral on a stan-
dard agar plate. This enables an accurate calculation of the
viable count, and as this is performed on brain–heart infusion
agar plates with 0, 0.5, 1, 2, 2.5 and 4 mg/L vancomycin, the
number of surviving bacteria at each antibiotic concentration
can be calculated and plotted against the vancomycin concen-
tration (Fig. 1). The AUC can be calculated, and compared
as a ratio with the standard Mu3 hGISA strain obtained by
dividing the value for the test strain by the area. This is for
Mu3, a ratio of ‡0.9 being taken as indicating hGISA.
Although this method has been invaluable for reference, it is
too laborious for use in either routine diagnostic microbiol-
ogy laboratories or large-scale epidemiological studies. It is
also essential that the method is carefully followed and not
subjected to arbitrary changes, which will lead to false-nega-
tive results [44].
It might be expected that standard manual disk and auto-
mated testing would be capable of detecting hGISA/GISA,
but a number of studies have demonstrated their shortcom-
ings [7,45,46]. There is, however, one report of the use of
low-concentration (15 lg) antibiotic disks on Mueller–Hinton
agar + 2% NaCl, using a MacFarlane 2.0 inoculum incubated
for 48 h, which differentiated VSSA from 18 hGISA strains
[47]. A full evaluation of this method could be warranted.
Even high-level vancomycin resistance in the case of some
VRSA strains (MIC of 32–64 mg/L) was not detected by
automated methods [13]. In the USA, the new CLSI break-
point for vancomycin sensitivity is an MIC of £2 mg/L, inter-
mediate sensitivity being deﬁned as 4–8 mg/L [12]. These
new standards and other acceptable screening and conﬁrma-
tory methods have been incorporated into an algorithm that
may be accessed at http://www.cdc.gov/ncidod/dhqp/ar_visa-
vrsa.html. Broth and agar microdilution, Etest with an inocu-
lum of 0.5 McFarland incubated for 24 h and Etest with an
inoculum of 2.0 McFarland with 48 h of incubation have all
been used with both vancomycin and teicoplainin [48]. Agar
plates containing 6 mg/L vancomycin are commercially avail-
able for screening, but are clearly unsuitable for the lower
CLSI breakpoint, and have also been found to be unreliable
[49].
There have been a number of evaluations of different,
recently published, phenotypic methods that have provided
useful indicators of the best methods for detecting hGISA/
GISA. The only large-scale multinational blinded evaluation of
phenotypic methods was reported by Wootton et al. in
2007. They distributed a panel of 48 strains with known gly-
copeptide susceptibilities to 12 laboratories, and three
screening methods were studied: brain–heart infusion agar
with 6 mg/L vancomycin (BHIA6V), Mueller–Hinton agar with
5 mg/L teicoplanin (MHA5T), and MET, using MIC values of
‡8 mg/L for vancomycin and/or teicoplanin [49]. Analysis of
the data showed that BHIA6V performed least effectively,
with <60% of isolates being correctly identiﬁed, and sensitiv-
ity and speciﬁcity values of 35.2% and 97.4%, respectively.
The variation among different laboratories in the percentage
of correctly identiﬁed strains ranged from 37% to 89%. This
high degree of variability with BHIA6V had also been previ-
ously reported in another study [13]. The overall percent-
ages of strains correctly identiﬁed and sensitivity and
speciﬁcity for both MHA5T and MET were very similar, with
MET performing just a little better, with a sensitivity and
speciﬁcity of 82.5% and 85.9%, respectively; MET also exhib-
ited the least inter-laboratory variation. The authors con-
cluded that BHIA6V was inappropriate for the identiﬁcation
of hGISA/GISA, and that MHA5T performed well and,
because of its low cost, could be viewed as the most useful
screening method, as, although MET performed slightly bet-
ter, the extra cost of undertaking the testing was not incon-
siderable for laboratories. Both MH5T and MET required the
higher inoculum, using a McFarland standard of 2, which also
further disrupts routine laboratory sensitivity testing when a
McFarland standard of 0.5 is typically used. A similar but
smaller study was carried out in The Netherlands by Voss
et al. [50] and reported in 2007. This study involved eight
Dutch laboratories, to which 25 blinded strains were distrib-
uted. The screening methods tested were BHIA6V, MHA5T,
and MHA5V, together with MET. Once again, considerable
variation was seen among laboratories. The authors used
Cohen’s kappa coefﬁcient (a value of 1.0 represents concor-
dance), calculated on results of quadruplicate samples of each
strain, to quantify the variation. The method with the least
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variation among laboratories was MHA5T. For VSSA, inter-
laboratory variation was extremely high for BHIA6V, with a
value of 0.3, as compared with 0.8 for MHA5T and 0.7 for
MET. A similar order of variability was seen for hGISA:
BHIA6V, 0.05; MHA5T, 0.93; and MET, 0.88. The authors
concluded that both BHIA with vancomycin and Mueller–
Hinton with vancomycin agar screening media lacked the
ability to detect hGISA. MHA5T was more sensitive, but still
somewhat inferior to MET, which had sensitivities of 98.5%
and 99.5% for hGISA and GISA, respectively. More recently,
a large-scale unblinded survey of 3189 isolates of MRSA from
2990 patients in the Republic of Ireland has been reported
[51]. All of these isolates were investigated using a variety of
agar screening methods and MET, and conﬁrmation of
hGISA/GISA was done by using PAP. No VRSA or GISA iso-
lates were detected, but 178 hGISA isolates were found,
which were conﬁrmed by PAP. The study examined the
effect on test results of both the preparation and density of
the inoculum used. It was found that the method used to
deliver the inoculum onto agar screening plates (12 strains/
plate) was quite important; the use of a micropipette to deli-
ver the inoculum of 10 lL onto the surface was much better
than the use of a standard 10-lL loop. The sensitivity and
speciﬁcity of the loop method were 61% and 77%; with the
pipette, the sensitivity increased to 100% but the speciﬁcity
fell to just 6% using MHA5T. The best methodology using a
screening agar was BHIA5T with an inoculum of 166 CFU/
mL (i.e. MacFarland 0.5), which gave a sensitivity of 100%
and speciﬁcity of 57% for hGISA strains. The speciﬁcity
increased to 84% when the method was used as a screening
technique followed by MET using teicoplanin, and
MIC ‡8 mg/L alone as the deﬁning characteristic. The
authors pointed out that the use of BHIA5T with a MacFar-
land standard of 0.5 had a practical advantage, in that it was
the same inoculum density as that used for standard CLSI/
BSAC diffusion susceptibility testing. The authors also rec-
ommended the use of PAP to conﬁrm suspected hGISA
strains identiﬁed using MET. Recently, evaluation of two pro-
totypes of MET strips for detecting hGISA/GISA has been
undertaken, using a worldwide collection of 150 strains com-
posed of 15 GISA and 60 hGISA strains, all deﬁned by PAP
[52]. These authors also found that BHI6V performed
poorly, with a sensitivity of 27%. MHA5T had much better
sensitivity, at 65%, but this was still lower than the experi-
mental GRD strip with the growth supplement added to it,
which, when incubated for 48 h on Mueller–Hinton agar con-
taining blood, gave a sensitivity of 94% and a speciﬁcity of
95%. Interestingly, MET performed on brain–heart infusion
agar with a MacFarland standard of 2 also had a sensitivity of
94%. The inoculum used here, however, had to be specially
prepared, whereas the incoculum used for the GRD strip
test was MacFarland 0.5, with the obvious advantages out-
lined above.
Molecular and Other Methods for
Identifying hGISA/GISA
The single most consistent difference between VISA and
hGISA/GISA is an alteration in peptidoglycan synthetic path-
ways, leading to the presence of a thickened cell wall [21].
These types of change in cell biochemistry can be detected
using cells divided on a metal surface and analysed by Fourier
transform infrared spectrometry. A recent study has applied
Fourier transform infrared spectrometry to the analysis of
35 GISA and 25 MRSA, and a high degree of differentiation
was obtained, so the method appears to be worthy of fur-
ther study [53].
It will be clear from the section on hGISA/GISA mecha-
nisms that no single genetic locus can be identiﬁed, and
therefore a single PCR test is very unlikely to be developed
to detect hGISA/GISA. A recent combined proteomic and
transcriptomic examination of three isogenic S. aureus strains
with different levels of resistance to glycopeptides revealed
94 differentially expressed genes and 178 proteins [54]. In an
effort to identify potential biomarkers of hGISA/GISA, com-
parative proteomics investigations were undertaken in
another study, using high-resolution two-dimensional gels
and iTRAQ mass tagging, identifying numerous proteins with
differential expression [55]. Interestingly, one protein,
SAV2095, predicted to be a lytic transglycosylase (SceD-like
protein), was signiﬁcantly induced in all hGISA/GISA isolates
relative to MRSA (p <0.001). The role that SAV2095 might
play in glycopeptide resistance is not clear, but SceD has a
function in nasal colonization, with increased expression in
the presence of salt [56]. These results suggest that the
SAV2095 expression level is worth investigating as a biomar-
ker for the rapid and reliable detection of hGISA/GISA
strains.
Conclusion
The clinical importance of hGISA/GISA is increasingly recog-
nized, a recent study demonstrating that, in patients with a
‘poor’ response to vancomycin therapy, there was a statisti-
cally signiﬁcant difference in the PAP AUC values [57]. It is
also recognized that hGISA/GISA may emerge from all of the
major multilocus sequence typing lineages of S. aureus [58]
and have recently been characterized in coagulase-negative
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staphylococci [59]. hGISA/GISA represent a challenge for
therapy, particularly as selection of a daptomycin-resistant
MRSA strain in vitro produced an hGISA phenotype in which
vraF and vraG were upregulated [35]. Paradoxically, GISA
strains have enhanced suspectibility to linezolid, making that
agent extremely useful and raising questions about the inter-
action of linezolid with the cell machinery of GISA [60].
There is currently no single reliable rapid test, either phe-
notypic or genetic, for hGISA/GISA. However, for laborato-
ries employing phenotypic test(s), Mueller–Hinton agar with
5 mg/L teicoplanin and a 10-lL inoculum of MacFarland 0.5
incubated for 48 h provides an inexpensive screening test.
Conﬁrmation using either MET (MIC ‡ 8mg/L for vancomy-
cin and/or teicoplanin using 200 lL of inoculum) or the new
GRD Etest on the following day is required. There are some
glimpses of potential targets for molecular tests (e.g. sceD
expression), but a deeper understanding of the resistance
mechanism of hGISA/GISA will be needed to accelerate test
development.
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